

P&T Motion History Antiemetics

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate Update	Reiteration of Prior Motion	Decision
aprepitant / fosaprepitant dolasetron doxylamine /pyridoxine HCL* granisetron granisetron transdermal patch* ondansetron ondansetron oral film* palonosetron rolapitant HCL*	<p>After considering the evidence of safety, efficacy and special populations for the treatment of nausea and vomiting related to chemotherapy, radiation therapy, and post operatively, I move that Granisetron, Ondansetron, Dolasetron, and Palonosetron are efficacious. The preferred drug list must include at least one medication that has both oral and intravenous routes approved in both adults and children. Granisetron, Ondansetron, and Palonosetron can be subject to therapeutic interchange within their routes of administration in the Washington preferred drug list. Aprepitant and Fosaprepitant are not to be included in the 5HT3 antagonist class.</p> <p>Motion: Cordy 2nd : Wiser</p>	August 17, 2016	Yes Johnson Klingel	Yes Harvey Rowe	Passed unanimous

*new drug identified in scan not eligible for inclusion on PDL.